All In Biotech

Drug Trial Radar · NCT04615923

HEALEY ALS Platform Trial - Regimen D Pridopidine

Last checked: Nov 19, 2026Latest source record: Aug 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 163 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

163

Actual

Start

Dec 18, 2020

Primary completion

Jul 14, 2022

Study completion Jul 14, 2022

Sponsor

Lead sponsor
Merit E. Cudkowicz, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Prilenia
First posted
Nov 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen D will evaluate the safety and efficacy of a single study drug, pridopidine, in participants with ALS.

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • PridopidineDrug

    Administration: Oral Dose: 45mg twice daily

  • Matching PlaceboDrug

    Administration: Oral Dose: one capsule twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease Progression as Assessed by the ALSFRS-R Total ScoreTime frame: Baseline to 24 Weeks
  2. Mortality Event RateTime frame: Baseline to 24 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Healey Center for ALS at Mass General

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.